Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 64

1.

iTRAQ proteomic identification of pVHL-dependent and -independent targets of Egln1 prolyl hydroxylase knockdown in renal carcinoma cells.

Haffey WD, Mikhaylova O, Meller J, Yi Y, Greis KD, Czyzyk-Krzeska MF.

Adv Enzyme Regul. 2009;49(1):121-32. doi: 10.1016/j.advenzreg.2008.12.004. Epub 2008 Dec 31. No abstract available.

2.

The von Hippel-Lindau tumor suppressor protein and Egl-9-Type proline hydroxylases regulate the large subunit of RNA polymerase II in response to oxidative stress.

Mikhaylova O, Ignacak ML, Barankiewicz TJ, Harbaugh SV, Yi Y, Maxwell PH, Schneider M, Van Geyte K, Carmeliet P, Revelo MP, Wyder M, Greis KD, Meller J, Czyzyk-Krzeska MF.

Mol Cell Biol. 2008 Apr;28(8):2701-17. doi: 10.1128/MCB.01231-07. Epub 2008 Feb 19.

3.

von Hippel-Lindau-dependent patterns of RNA polymerase II hydroxylation in human renal clear cell carcinomas.

Yi Y, Mikhaylova O, Mamedova A, Bastola P, Biesiada J, Alshaikh E, Levin L, Sheridan RM, Meller J, Czyzyk-Krzeska MF.

Clin Cancer Res. 2010 Nov 1;16(21):5142-52. doi: 10.1158/1078-0432.CCR-09-3416. Epub 2010 Oct 26.

4.

Evidence for a stereoelectronic effect in human oxygen sensing.

Loenarz C, Mecinović J, Chowdhury R, McNeill LA, Flashman E, Schofield CJ.

Angew Chem Int Ed Engl. 2009;48(10):1784-7. doi: 10.1002/anie.200805427.

PMID:
19180614
5.
6.

Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation.

Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, von Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, Ratcliffe PJ.

Science. 2001 Apr 20;292(5516):468-72. Epub 2001 Apr 5.

8.

Mutation analysis of HIF prolyl hydroxylases (PHD/EGLN) in individuals with features of phaeochromocytoma and renal cell carcinoma susceptibility.

Astuti D, Ricketts CJ, Chowdhury R, McDonough MA, Gentle D, Kirby G, Schlisio S, Kenchappa RS, Carter BD, Kaelin WG Jr, Ratcliffe PJ, Schofield CJ, Latif F, Maher ER.

Endocr Relat Cancer. 2010 Dec 21;18(1):73-83. doi: 10.1677/ERC-10-0113. Print 2011 Feb.

9.

Clusterin is a secreted marker for a hypoxia-inducible factor-independent function of the von Hippel-Lindau tumor suppressor protein.

Nakamura E, Abreu-e-Lima P, Awakura Y, Inoue T, Kamoto T, Ogawa O, Kotani H, Manabe T, Zhang GJ, Kondo K, Nosé V, Kaelin WG Jr.

Am J Pathol. 2006 Feb;168(2):574-84.

10.

Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor.

Ivan M, Haberberger T, Gervasi DC, Michelson KS, Günzler V, Kondo K, Yang H, Sorokina I, Conaway RC, Conaway JW, Kaelin WG Jr.

Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13459-64. Epub 2002 Sep 26.

11.

A feedback loop involving the Phd3 prolyl hydroxylase tunes the mammalian hypoxic response in vivo.

Minamishima YA, Moslehi J, Padera RF, Bronson RT, Liao R, Kaelin WG Jr.

Mol Cell Biol. 2009 Nov;29(21):5729-41. doi: 10.1128/MCB.00331-09. Epub 2009 Aug 31.

12.

Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.

Zatyka M, da Silva NF, Clifford SC, Morris MR, Wiesener MS, Eckardt KU, Houlston RS, Richards FM, Latif F, Maher ER.

Cancer Res. 2002 Jul 1;62(13):3803-11. Erratum in: Cancer Res. 2015 Sep 15;75(18):3993.

13.

New cancer targets emerging from studies of the Von Hippel-Lindau tumor suppressor protein.

Kaelin WG Jr.

Ann N Y Acad Sci. 2010 Oct;1210:1-7. doi: 10.1111/j.1749-6632.2010.05781.x.

14.

Regulation of HIF prolyl hydroxylases by hypoxia-inducible factors.

Aprelikova O, Chandramouli GV, Wood M, Vasselli JR, Riss J, Maranchie JK, Linehan WM, Barrett JC.

J Cell Biochem. 2004 Jun 1;92(3):491-501. Erratum in: J Cell Biochem. 2004 Oct 15;93(3):639.

PMID:
15156561
15.

Multiple factors affecting cellular redox status and energy metabolism modulate hypoxia-inducible factor prolyl hydroxylase activity in vivo and in vitro.

Pan Y, Mansfield KD, Bertozzi CC, Rudenko V, Chan DA, Giaccia AJ, Simon MC.

Mol Cell Biol. 2007 Feb;27(3):912-25. Epub 2006 Nov 13.

16.

A novel erythrocytosis-associated PHD2 mutation suggests the location of a HIF binding groove.

Percy MJ, Furlow PW, Beer PA, Lappin TR, McMullin MF, Lee FS.

Blood. 2007 Sep 15;110(6):2193-6. Epub 2007 Jun 19.

17.

[Mutations in hypoxia-inducible factor and its regulatory molecules in familial erythrocytosis].

Komatsu N.

Rinsho Ketsueki. 2009 Oct;50(10):1589-94. Review. Japanese. No abstract available.

PMID:
19915370
18.

HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia.

Berra E, Benizri E, Ginouvès A, Volmat V, Roux D, Pouysségur J.

EMBO J. 2003 Aug 15;22(16):4082-90.

19.

Erythrocytosis-associated HIF-2alpha mutations demonstrate a critical role for residues C-terminal to the hydroxylacceptor proline.

Furlow PW, Percy MJ, Sutherland S, Bierl C, McMullin MF, Master SR, Lappin TR, Lee FS.

J Biol Chem. 2009 Apr 3;284(14):9050-8. doi: 10.1074/jbc.M808737200. Epub 2009 Feb 10.

20.

Regulation of cellular levels of Sprouty2 protein by prolyl hydroxylase domain and von Hippel-Lindau proteins.

Anderson K, Nordquist KA, Gao X, Hicks KC, Zhai B, Gygi SP, Patel TB.

J Biol Chem. 2011 Dec 9;286(49):42027-36. doi: 10.1074/jbc.M111.303222. Epub 2011 Oct 17.

Supplemental Content

Support Center